Regeneron Resumes Enrollment of FL and DLBCL Patients in Odronextamab Trials - SC Read more about Regeneron Resumes Enrollment of FL and DLBCL Patients in Odronextamab Trials - SC
再鼎医药合作伙伴安进公司在研靶向治疗药物Bemarituzumab获美国FDA突破性疗法认证 Read more about 再鼎医药合作伙伴安进公司在研靶向治疗药物Bemarituzumab获美国FDA突破性疗法认证
再鼎医药合作伙伴Novocure公司于2021 AACR年会上发布26篇肿瘤电场治疗相关研究报告：肿瘤电场治疗或具有广泛适用性 Read more about 再鼎医药合作伙伴Novocure公司于2021 AACR年会上发布26篇肿瘤电场治疗相关研究报告：肿瘤电场治疗或具有广泛适用性
再鼎医药合作伙伴Turning Point Therapeutics公司宣布3个候选药物新的临床前数据 Read more about 再鼎医药合作伙伴Turning Point Therapeutics公司宣布3个候选药物新的临床前数据
argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis - SC Read more about argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis - SC
Turning Point Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days - SC Read more about Turning Point Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days - SC
argenx Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis - SC Read more about argenx Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis - SC
Turning Point Therapeutics Reports Updated Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib in Patients With ROS1-Positive TKI-Naïve Non-Small Cell Lung Cancer - SC Read more about Turning Point Therapeutics Reports Updated Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib in Patients With ROS1-Positive TKI-Naïve Non-Small Cell Lung Cancer - SC
再鼎医药合作伙伴MacroGenics公司宣布在《JAMA肿瘤学》上发表MARGENZA™的SOPHIA研究结果 Read more about 再鼎医药合作伙伴MacroGenics公司宣布在《JAMA肿瘤学》上发表MARGENZA™的SOPHIA研究结果
Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) - SC Read more about Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) - SC